Early responders within seven days of dupilumab treatment for severe asthma evaluated by patient-reported outcome: a pilot study

BACKGROUND: The management of severe asthma-associated symptoms is essential since they are distressing to the affected patients, and also greatly impair their quality of life. Dupilumab, a monoclonal antibody, blocks interleukin (IL)-4 and IL-13 signaling, both of which are crucial in acquired and...

Descripción completa

Detalles Bibliográficos
Autores principales: Tani, Nozomi, Kataoka, Nobutaka, Kunimatsu, Yusuke, Tachibana, Yusuke, Sugimoto, Takumi, Sato, Izumi, Ogura, Yuri, Hirose, Kazuki, Takeda, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993019/
https://www.ncbi.nlm.nih.gov/pubmed/33815789
http://dx.doi.org/10.4081/mrm.2021.736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993019/
https://www.ncbi.nlm.nih.gov/pubmed/33815789
http://dx.doi.org/10.4081/mrm.2021.736

Ejemplares similares